This post has been read 6449 times!
KUWAIT CITY, July 6: According to health sources, the Ministry of Health has finally obtained approvals from the regulatory authorities for the purchase and supply of medical solutions to the Industrial College by the Standing Committee for the Unified Procurement of the Executive Office of the Gulf Health Ministers Council, at a cost of approximately KD 674,000, reports Al-Qabas daily. They explained that the regulatory authorities also agreed to extend the contract related to health insurance services for retired citizens – Afya – for a period of three months, starting from July 16 at a cost of up to KD 44.4 million. The authorities also agreed to amend the amount of the sixth extension of the contract for the supply of medical support services (lab technician, radiology technician and pharmacy technician) in Sabah Health Zone for a period of one year from March 5 to July 4, 2023. It was changed to KD 2.2 million from KD 3.2 million, after reducing the number of technicians to 298 from 433.
This comes in light of the continuous work of the concerned authorities in the ministry to expedite the pace of importing medicines and medical supplies, and supplying them to warehouses and health facilities without any hindrances, search for solutions to eliminate the documentary cycle related to supply requests that pass through more than one sector and a government entity, and ensure deserving beneficiaries receive their treatment protocols prescribed to them by the medical staff without delay.
The sources affirmed that the ministry is working to address some of the defects that were obstructing the procurement of medicines and medical supplies regularly recently, including the mechanism of paper purchase requests, and obtaining the necessary approvals from the boards of medical departments, the Central Agency for Public Tenders and the State Audit Bureau. They revealed that the ministry is looking for solutions for the payment of the delayed dues to local companies, which are committed to their role with companies and factories that produce medicines for chronic and other diseases